The schedule IV labeling is a minor issue as far as physicians are concerned and the BLOOM-DM data speak for themselves.

FORBES: Merry Christmas! Here's Our Bad News

And Arena almost certainly wants to submit the data from its ongoing Bloom-DM study of lorcaserin in diabetes.

FORBES: How Long Will It Take For Arena's Obesity Drug To Be Approved?